Stock listing
NASDAQ:COLL Collegium Pharmaceutical, Inc. Stock
Home listing (NASDAQ) of Collegium Pharmaceutical, Inc.
Follow Collegium Pharmaceutical, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:COLL
$24.72 USD -1.21 (-4.7%)
Close on Nov 20, 2026
- Day range
- $24.64 – $25.43 USDNov 20, 2026
- Volume
- 528,016 sharesNov 20, 2026
- Market cap
- $804.8M USDAt the close on Nov 20, 2026 · price × 32.56M shares outstanding
- 52-week range
- $21.43 – $50.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.83M USDMedian day 707,366 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:COLL · Home | $24.72 USD | -1.21 (-4.7%) | 528,016 | $25.06 | $25.43 | $24.64 | $25.93 | Close on Nov 20, 2026 |
| Frankfurt:354 | €22.20 EUR | -0.40 (-1.8%) | — | €22.40 | €22.40 | €22.20 | €22.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COLL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $24.72 | -1.21 | -4.7% | $25.06 | $25.43 | $24.64 | 528,016 | |
| $25.93 | +0.38 | +1.5% | $25.36 | $26.24 | $25.01 | 494,458 | |
| $25.55 | +0.12 | +0.5% | $25.14 | $25.67 | $25.00 | 365,231 | |
| $25.43 | +0.11 | +0.4% | $25.68 | $25.68 | $25.04 | 494,891 | |
| $25.32 | +0.37 | +1.5% | $25.01 | $25.44 | $24.61 | 395,541 | |
| $24.95 | +0.14 | +0.6% | $25.06 | $25.13 | $24.52 | 479,879 | |
| $24.81 | +0.34 | +1.4% | $24.13 | $24.83 | $23.99 | 500,398 | |
| $24.47 | -0.24 | -1.0% | $24.46 | $24.95 | $24.14 | 851,836 | |
| $24.71 | +0.50 | +2.1% | $24.41 | $25.09 | $24.22 | 628,831 | |
| $24.21 | -0.95 | -3.8% | $24.06 | $24.80 | $23.71 | 775,573 | |
| $25.16 | +1.49 | +6.3% | $25.74 | $26.39 | $24.32 | 1,572,971 | |
| $23.67 | -0.06 | -0.3% | $24.11 | $24.48 | $23.42 | 803,976 | |
| $23.73 | +0.05 | +0.2% | $23.67 | $23.92 | $23.49 | 524,866 | |
| $23.68 | -0.12 | -0.5% | $23.96 | $24.08 | $23.25 | 600,667 | |
| $23.80 | -0.23 | -1.0% | $24.28 | $24.50 | $23.66 | 401,929 | |
| $24.03 | +0.80 | +3.4% | $23.70 | $24.18 | $23.57 | 656,454 | |
| $23.23 | +0.23 | +1.0% | $22.78 | $23.31 | $22.67 | 406,091 | |
| $23.00 | -0.21 | -0.9% | $23.08 | $23.29 | $22.74 | 486,609 | |
| $23.21 | +0.25 | +1.1% | $22.96 | $23.52 | $22.92 | 518,252 | |
| $22.96 | -0.54 | -2.3% | $23.30 | $23.49 | $22.15 | 662,374 | |
| $23.50 | +0.585 | +2.6% | $23.03 | $23.85 | $22.94 | 738,765 | |
| $22.92 | -0.315 | -1.4% | $23.13 | $23.15 | $22.58 | 480,416 | |
| $23.23 | +0.22 | +1.0% | $23.54 | $23.84 | $22.90 | 536,154 | |
| $23.01 | -0.18 | -0.8% | $22.99 | $23.54 | $22.74 | 713,872 | |
| $23.19 | +0.01 | 0.0% | $23.40 | $23.41 | $22.86 | 558,736 | |
| $23.18 | +0.67 | +3.0% | $23.06 | $24.04 | $23.06 | 1,001,996 | |
| $22.51 | +0.98 | +4.6% | $21.65 | $22.56 | $21.47 | 920,241 | |
| $21.53 | -0.52 | -2.4% | $22.05 | $22.21 | $21.46 | 846,421 | |
| $22.05 | -0.04 | -0.2% | $22.14 | $22.28 | $21.79 | 528,695 | |
| $22.09 | -0.02 | -0.1% | $22.01 | $22.40 | $21.77 | 438,440 | |
| $22.11 | +0.18 | +0.8% | $22.03 | $22.18 | $21.79 | 532,922 | |
| $21.93 | +0.05 | +0.2% | $21.88 | $22.15 | $21.73 | 783,474 | |
| $21.88 | +0.01 | 0.0% | $22.06 | $22.32 | $21.68 | 634,061 | |
| $21.87 | -0.15 | -0.7% | $22.23 | $22.26 | $21.67 | 975,380 | |
| $22.02 | +0.18 | +0.8% | $21.97 | $22.38 | $21.64 | 694,061 | |
| $21.84 | +0.02 | +0.1% | $21.94 | $22.28 | $21.43 | 1,000,105 | |
| $21.82 | -0.41 | -1.8% | $22.14 | $22.33 | $21.82 | 811,563 | |
| $22.23 | -0.40 | -1.8% | $22.61 | $22.92 | $21.62 | 1,022,590 | |
| $22.63 | +0.10 | +0.4% | $22.63 | $23.17 | $22.36 | 687,383 | |
| $22.53 | -0.11 | -0.5% | $22.58 | $22.91 | $22.29 | 503,430 | |
| $22.64 | +0.19 | +0.8% | $22.27 | $22.77 | $21.90 | 650,116 | |
| $22.45 | -0.33 | -1.4% | $23.23 | $23.69 | $21.77 | 878,442 | |
| $22.78 | -0.26 | -1.1% | $23.46 | $23.52 | $22.64 | 808,250 | |
| $23.04 | +0.27 | +1.2% | $22.78 | $23.23 | $22.51 | 928,273 | |
| $22.77 | +0.39 | +1.7% | $22.17 | $22.93 | $22.07 | 1,992,650 | |
| $22.38 | +0.19 | +0.9% | $22.36 | $22.64 | $22.08 | 707,366 | |
| $22.19 | +0.35 | +1.6% | $21.84 | $22.80 | $21.68 | 1,154,222 | |
| $21.84 | -0.97 | -4.3% | $22.81 | $22.92 | $21.65 | 954,003 | |
| $22.81 | +0.06 | +0.3% | $22.80 | $23.19 | $22.50 | 825,547 | |
| $22.75 | -0.17 | -0.7% | $23.02 | $23.25 | $22.64 | 661,300 | |
| $22.92 | -0.44 | -1.9% | $23.38 | $23.45 | $22.72 | 889,098 | |
| $23.36 | -0.01 | 0.0% | $23.56 | $24.11 | $23.12 | 1,077,597 | |
| $23.37 | -0.16 | -0.7% | $23.33 | $23.82 | $23.11 | 1,114,851 | |
| $23.53 | -0.17 | -0.7% | $23.54 | $24.32 | $23.37 | 901,142 | |
| $23.70 | -0.60 | -2.5% | $24.30 | $24.43 | $23.64 | 859,167 | |
| $24.30 | +0.30 | +1.3% | $24.15 | $24.82 | $23.84 | 852,660 | |
| $24.00 | -0.61 | -2.5% | $24.85 | $25.46 | $23.93 | 1,407,000 | |
| $24.61 | -0.74 | -2.9% | $25.12 | $25.43 | $24.47 | 1,035,431 | |
| $25.35 | -1.09 | -4.1% | $26.32 | $26.69 | $25.16 | 813,953 | |
| $26.44 | -1.07 | -3.9% | $27.26 | $27.41 | $26.21 | 850,153 | |
| $27.51 | +0.04 | +0.1% | $27.58 | $28.25 | $27.01 | 613,193 | |
| $27.47 | +0.12 | +0.4% | $27.47 | $27.76 | $27.13 | 551,895 | |
| $27.35 | +0.24 | +0.9% | $27.08 | $27.99 | $26.87 | 758,446 | |
| $27.11 | -0.43 | -1.6% | $27.68 | $27.68 | $26.96 | 704,929 | |
| $27.54 | -1.20 | -4.2% | $28.35 | $28.50 | $27.25 | 606,611 |
- Ticker
- NASDAQ:COLL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Latest earnings call · Nov 5, 2026
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 5, 2026
Q3 2026 Earnings Presentation
Earnings · 48 slides
Latest news
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Nov 5, 2026
Closed $25.16 (+6.3%) on Nov 5, 2026
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Oct 29, 2026
Closed $24.03 (+3.4%) on Oct 29, 2026
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 22, 2026
Closed $23.50 (+2.6%) on Oct 22, 2026
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Oct 21, 2026
Closed $22.92 (-1.4%) on Oct 21, 2026
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Oct 6, 2026
Closed $21.88 (0.0%) on Oct 6, 2026
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Aug 6, 2026
Closed $29.11 (-18.6%) on Aug 6, 2026
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 23, 2026
Closed $35.59 (+2.5%) on Jul 23, 2026
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
Jul 20, 2026
Closed $35.54 (-1.5%) on Jul 20, 2026
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2026
Closed $33.38 (+2.1%) on Jun 5, 2026
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $33.68 (-0.3%) on May 27, 2026
Collegium Pharmaceutical, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 23 in the last 12 months · 137 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 31 calls with a replay · 31 with a transcript · latest Nov 5, 2026
- Decks
- 37 decks · latest Nov 5, 2026
Where Collegium Pharmaceutical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:COLL · Home listing · This page | NASDAQ | United States | USD |
| gettex:354 | gettex | Germany | EUR |
| LS Exchange:A14SUV | LS Exchange | Germany | EUR |
| Lang & Schwarz:A14SUV | Lang & Schwarz | Germany | EUR |
| BOATS:COLL | BOATS | United States | USD |
| Frankfurt:354 | Frankfurt | Germany | EUR |
| Dusseldorf:354 | Dusseldorf | Germany | EUR |
| Munich:354 | Munich | Germany | EUR |
| Stuttgart:354 | Stuttgart | Germany | EUR |
| Tradegate:354 | Tradegate | Germany | EUR |
Valuation
P/E 21.1× against a median of 21.2×: 5th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.75B USD
- P/E
- 21.1×
- EV/sales
- 2.1×
- EV/EBITDA
- 9.5×
- Price/book
- 2.7×
- Gross margin
- 59.1%
- Operating margin
- 15.2%
- Net margin
- 4.7%
- Debt to equity
- 3.7×
- Beta vs S&P 500
- 0.26
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. · NASDAQ:COLL | US$804.8M | US$1.75B | 21.1× | 2.1× | 9.5× | 2.7× | 4.7% | 3.7× | 0.26 |
| Shandong Xinhua Pharmaceutical Company Limited Class A · SZSE:000756 | US$839.2M | US$753.6M | 24.5× | 0.6× | n/a | 1.1× | 2.8% | 0.1× | n/a |
| Sichuan Huiyu Pharmaceutical Co. Ltd. Class A · SSE:688553 | US$829.6M | US$414.4M | 42.6× | 2.5× | n/a | 1.5× | 11.6% | 0.0× | n/a |
| Lotus Pharmaceutical Co., Ltd. · TWSE:1795 | US$820.5M | US$2.40B | 7.2× | 2.8× | 8.7× | 1.1× | 13.2% | 2.4× | n/a |
| HK inno.N Corporation · KRX:195940 | US$817.4M | US$841.6M | 12.7× | 1.0× | n/a | 0.8× | 8.0% | 0.1× | n/a |
| Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A · SZSE:301246 | US$805.1M | US$623.7M | 17.7× | 1.6× | n/a | 1.2× | 11.9% | 0.1× | n/a |
| Sanofi India Limited · NSE:SANOFI | US$796.8M | US$758.0M | 20.3× | 3.9× | 13.8× | 8.9× | 20.0% | 0.0× | n/a |
| Shanghai Haixin Group Co., Ltd. Class A · SSE:600851 | US$786.1M | US$634.5M | 27.5× | 6.6× | n/a | 1.1× | 29.8% | 0.0× | n/a |
| Hunan Er-Kang Pharmaceutical Co., Ltd. Class A · SZSE:300267 | US$778.4M | US$634.7M | n/a | 3.8× | n/a | 1.3× | −31.4% | 0.0× | n/a |
| Zhejiang Ausun Pharmaceutical Co., Ltd. Class A · SSE:603229 | US$778.4M | US$638.7M | n/a | 5.6× | n/a | 2.3× | −0.6% | 0.0× | n/a |
| Jinghua Pharmaceutical Group Co., Ltd. Class A · SZSE:002349 | US$772.9M | US$604.8M | 22.2× | 2.7× | n/a | 1.8× | 15.7% | 0.0× | n/a |
| Median of the others | US$801.0M | US$636.7M | 21.2× | 2.8× | 11.3× | 1.2× | 11.7% | 0.0× |
Forecasts
5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 44.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 7.46 · 7 analysts
- Revenue, year to Dec 2026
- 832M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Vikram Karnani | PRESIDENT & CHIEF EXECUTIVE OFFICER |
| Colleen Tupper | Executive Vice President, Chief Financial Officer |
| David Dieter | Executive Vice President, General Counsel |
| Jessica Cotrone | Senior Vice President, Corporate Communications & Corporate Affairs |
| Jessica Cotrone Senior | Vice President, Corporate Communications & Corporate Affairs |
| Jane Gonnerman | Executive Vice President, Strategy & Corporate Development |
| Scott Sudduth | Executive Vice President, Head of Technical Operations |
| Thomas Smith | Executive Vice President, Chief Medical Officer |
| Arun Padmanabhan | General Manager, Pain |
| Dean J. Patras | Chief People Officer |
| Ingrid McPhilliamy | General Manager, ADHD |
Board
| Director | Role |
|---|---|
| Gino Santini | Chairman of the Board |
| Carlos V. Paya | Director |
| Garen Bohlin | Director |
| John G. Freund | Director |
| Michael G. Donovan | Director |
| Nancy S. Lurker | Director |
| Rita Balice-Gordon | Director |
| Vikram Karnani | PRESIDENT & CHIEF EXECUTIVE OFFICER |
Events
Calls
| Call | When | Status |
|---|---|---|
| Collegium Pharmaceutical (NASDAQ:COLL) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Collegium Pharmaceutical (NASDAQ:COLL) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 31 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | +6.3% |
| Q2 2026 | Aug 6, 2026 · Before open | −18.6% |
| Q1 2026 | May 7, 2026 · Before open | +7.7% |
| Q4 2025 | Feb 26, 2026 | −8.9% |
| Q3 2025 | Nov 6, 2025 · Before open | +13.4% |
| Q2 2025 | Aug 7, 2025 · Before open | +10.7% |
| Q1 2025 | May 8, 2025 · After close | +5.9% |
| Q4 2024 | Feb 20, 2025 · After close | −2.1% |
| Q3 2024 | Nov 7, 2024 · After close | −7.3% |
| Q2 2024 | Aug 8, 2024 · After close | +0.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −16.8% |
| Q4 2023 | Feb 22, 2024 · After close | +10.8% |
| Q3 2023 | Nov 7, 2023 · After close | +6.6% |
| Q2 2023 | Aug 3, 2023 · After close | +6.7% |
| Q1 2023 | May 4, 2023 · After close | +3.2% |
| Q4 2022 | Feb 23, 2023 · After close | +0.9% |
| Q3 2022 | Nov 3, 2022 · After close | +4.5% |
| Q2 2022 | Aug 4, 2022 · After close | +8.6% |
| Q1 2022 | May 10, 2022 · After close | −0.1% |
| Q4 2021 | Feb 24, 2022 · After close | −9.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 48 slides | Nov 5, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 22 slides | Nov 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 22 slides | Aug 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 50 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 24 slides | May 7, 2026 |
| Merger or Acquisition (March 2026) | Merger or acquisition | 15 slides | Mar 19, 2026 |
| FY2025 Earnings Presentation | Earnings | 24 slides | Feb 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 49 slides | Jan 8, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 23 slides | Nov 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 23 slides | Aug 7, 2025 |
All 37 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2025 Earnings Presentation | Earnings | 48 slides | Aug 7, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 22 slides | May 8, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 24 slides | Feb 27, 2025 |
| Investor Presentation (January 2025) | Investor deck | 41 slides | Jan 8, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 23 slides | Nov 7, 2024 |
| Investor Presentation (September 2024) | Investor deck | 45 slides | Sep 4, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 23 slides | Aug 8, 2024 |
| Merger or Acquisition (July 2024) | Merger or acquisition | 13 slides | Jul 29, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 24 slides | May 9, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 24 slides | Feb 22, 2024 |
| Investor Presentation (January 2024) | Investor deck | 37 slides | Jan 3, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 22 slides | Nov 7, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 23 slides | Aug 3, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 20 slides | May 4, 2023 |
| FY2022 Earnings Presentation | Earnings | 22 slides | Feb 23, 2023 |
| Investor Presentation (January 2023) | Investor deck | 35 slides | Jan 4, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 21 slides | Nov 3, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 19 slides | Aug 4, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 25 slides | May 10, 2022 |
| Investor Presentation (April 2022) | Investor deck | 39 slides | Apr 13, 2022 |
| FY2021 Earnings Presentation | Earnings | 17 slides | Feb 24, 2022 |
| Merger or Acquisition (February 2022) | Merger or acquisition | 11 slides | Feb 14, 2022 |
| Investor Presentation (February 2022) | Investor deck | 17 slides | February 2022 |
| Q2 2021 Earnings Presentation | Earnings | 20 slides | Aug 5, 2021 |
| Investor Presentation (June 2021) | Investor deck | 20 slides | Jun 2, 2021 |
| Investor Presentation (January 2019) | Investor deck | 20 slides | Jan 7, 2019 |
| Merger or Acquisition (December 2017) | Merger or acquisition | 14 slides | Dec 4, 2017 |
IPO
Priced at US$12.00 a share on May 6, 2015.
- Price
- US$12.00 a share
- Shares offered
- 5,800,000 shares of common stock
- Offering size
- US$69.6 million
- Underwriters' option
- Up to 870,000 more shares
- Listing
- COLL on the Nasdaq Global Select Market
- Underwriters
- Jefferies, Piper Jaffray, Wells Fargo Securities, Needham & Company · In the order on the cover
- Shares delivered
- On or about May 12, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 3, 2015 |
| Filed publicly | Apr 2, 2015 |
| Amended once | Apr 27, 2015 |
| Shares registered with an exchange | May 1, 2015 |
| Declared effective by the SEC | May 6, 2015 |
| Final prospectus, with the price | May 7, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 7, 2015 |
| EFFECT · Notice that a registration is effective | May 6, 2015 |
| CERTNAS · Nasdaq's certificate of listing | May 5, 2015 |
| CORRESP · Letter to the SEC | May 4, 2015 |
| CORRESP · Letter to the SEC | May 4, 2015 |
| CORRESP · Letter to the SEC | May 4, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | May 1, 2015 |
| S-1/A · Registration statement, amended | Apr 27, 2015 |
| CORRESP · Letter to the SEC | Apr 22, 2015 |
| S-1 · Registration statement | Apr 2, 2015 |
All 13 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Mar 31, 2015 |
| DRSLTR · Letter to the SEC with a draft | Mar 3, 2015 |
| DRS · Draft registration statement | Mar 3, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 780.6M | 631.4M | 566.8M | 463.9M | 276.9M | 310.0M | 296.7M | 280.4M | 28.5M | 1.71M |
| Cost of revenue | 317.3M | 254.1M | 240.6M | 254.4M | 126.3M | 130.2M | 193.7M | 165.7M | 2.60M | 213.0K |
| Gross profit | 463.3M | 377.3M | 326.2M | 209.5M | 150.6M | 179.8M | 103.0M | 114.7M | 25.9M | 1.50M |
| Research and development | 0 | 0 | 3.98M | 9.45M | 9.77M | 10.3M | 8.66M | 8.57M | 14.9M | |
| Selling, general and administrative | 284.8M | 210.4M | 159.2M | 172.2M | 119.0M | 113.8M | 116.4M | 126.8M | 92.8M | 80.6M |
| Operating income | 179.6M | 169.9M | 167.0M | 33.3M | 17.6M | 56.2M | -23.7M | -20.7M | -75.4M | -94.1M |
| Depreciation and amortization | 4.18M | 3.86M | 3.50M | 2.68M | 1.74M | 870.0K | 731.0K | 1.07M | 594.0K | 655.0K |
| EBITDA | 183.8M | 173.8M | 170.5M | 36.0M | 19.4M | 57.1M | -23.0M | -19.6M | -74.9M | -93.4M |
| Interest expense | 82.3M | 74.0M | 83.3M | 63.2M | 21.0M | 28.9M | 909.0K | 20.1M | 582.0K | 94.0K |
| Income before tax | 92.6M | 98.6M | 75.7M | -28.8M | -3.37M | 27.6M | -22.7M | -39.1M | -74.9M | -94.2M |
| Income tax | 29.7M | 29.4M | 27.6M | -3.85M | -74.9M | 830.0K | 0 | -110.9M | -1.16M | 94.0K |
| Net income | 62.9M | 69.2M | 48.2M | -25.0M | 71.5M | 26.8M | -22.7M | -39.1M | -74.9M | -94.2M |
| Earnings per share, basic | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 | 0.78 | -0.68 | -1.19 | -2.47 | -3.88 |
| Earnings per share, diluted | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 | -1.19 | -2.47 | -3.88 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 231.3M | 70.6M | 238.9M | 173.7M | 186.4M | 174.1M | 170.0M | 146.6M | 118.7M | 153.2M |
| Short-term investments | 155.4M | 92.2M | 71.6M | 0 | 0 | 0 | ||||
| Receivables | 211.3M | 228.5M | 179.5M | 183.1M | 105.8M | 83.3M | 73.0M | 77.9M | 9.97M | 2.13M |
| Inventory | 40.9M | 35.6M | 32.3M | 46.5M | 17.4M | 15.6M | 9.64M | 7.82M | 1.81M | 1.32M |
| Current assets | 691.4M | 482.3M | 537.6M | 420.0M | 315.5M | 277.9M | 255.7M | 237.5M | 133.5M | 158.6M |
| Property, plant and equipment | 12.0M | 14.3M | 16.0M | 19.5M | 19.5M | 19.0M | 11.9M | 9.27M | 1.83M | 1.04M |
| Goodwill | 145.9M | 162.3M | 133.9M | 133.7M | 0 | 0 | 0 | |||
| Total assets | 1.66B | 1.66B | 1.14B | 1.17B | 692.1M | 643.8M | 306.3M | 291.2M | 135.6M | 162.0M |
| Accounts payable | 10.7M | 3.93M | 8.69M | 3.49M | 4.19M | 10.0M | 6.25M | 12.2M | 5.68M | 9.11M |
| Current liabilities | 440.0M | 509.5M | 457.9M | 433.7M | 279.6M | 239.5M | 201.8M | 189.1M | 31.5M | 25.6M |
| Long-term debt | 780.3M | 787.9M | 483.8M | 538.5M | 201.6M | 209.6M | 7.67M | 9.86M | 0 | 1.48M |
| Total debt | 940.6M | 859.3M | 674.3M | 709.2M | 258.8M | 266.6M | 11.5M | 11.5M | 1.48M | 4.15M |
| Total liabilities | 1.36B | 1.43B | 947.9M | 979.3M | 489.1M | 457.8M | 218.9M | 199.7M | 31.5M | 27.1M |
| Shareholders' equity | 301.7M | 228.8M | 195.4M | 194.8M | 202.9M | 186.0M | 87.4M | 91.6M | 104.1M | 134.9M |
| Shares outstanding | 31.7M | 31.4M | 31.9M | 33.8M | 33.7M | 34.6M | 33.7M | 33.3M | 32.8M | 29.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 329.3M | 205.0M | 274.7M | 124.2M | 103.6M | 93.9M | 27.8M | 169.4M | -67.0M | -75.1M |
| Capital spending | -1.74M | -1.65M | -461.0K | -1.62M | -1.94M | -5.55M | -6.44M | -5.48M | -990.0K | -477.0K |
| Free cash flow | 327.6M | 203.3M | 274.3M | 122.6M | 101.6M | 88.4M | 21.3M | 163.9M | -68.0M | -75.5M |
| Cash from investing | -63.5M | -287.8M | -70.8M | -573.7M | -1.94M | -373.8M | -6.44M | -24.4M | -990.0K | -2.98M |
| Cash from financing | -110.2M | -60.6M | -140.2M | 436.7M | -89.3M | 286.5M | 2.04M | -117.2M | 33.5M | 135.6M |
| Dividends paid | -9.10M | -12.7M | -7.33M | -736.0K | -24.6M | |||||
| Share buybacks | -25.1M | -60.0M | -75.0M | -14.1M | -47.9M | -2.25M | -822.0K | -560.0K | 1.14M | 24.6M |
| Change in cash | 155.5M | -143.4M | 63.8M | -12.7M | 12.3M | 6.64M | 23.4M | 27.8M | -34.5M | 57.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Jun 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 1, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 1, 2026 | Offer document | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
| 8-K · Current report | May 15, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Acquisition or disposal | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 8, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 7, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 7, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 7, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 19, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Mar 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 8-K · Current report | Dec 30, 2025 | Material contract | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 POS | Jun 6, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 6, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 19, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 2, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 19, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 10, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 14, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Nov 14, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 13, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 4, 2024 | Acquisition or disposal | SEC |
| S-8 · Registration statement for employee plans | Aug 15, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Aug 12, 2024 | Other filings | SEC |
This page holds 200 of 875 filings. Open Filings
Cap table
Built by 6ix from Collegium Pharmaceutical, Inc.’s releases
- Common shares
- 32,555,613
- Fully diluted
- 32,555,613
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 32,555,613 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 32,555,613 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John G. Freund Other companies: SI-BONE, Inc. (Director · Since at least Oct 16, 2018); Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Jun 6, 2024 · Past); Protara Therapeutics, Inc. (Director · Oct 21, 2014 – Nov 8, 2019 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Dec 10, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Hansen Medical Inc (Director · Nov 15, 2006 – Jun 17, 2009 · Past); XenoPort Inc (Director · May 2, 2006 – Jul 5, 2016 · Past) | Director · Since at least May 6, 2015 |
| Theodore R Schroeder Other companies: Phathom Pharmaceuticals, Inc. (Director · Since at least Apr 16, 2025); Cidara Therapeutics Inc (Director · Since at least Apr 14, 2015); Nabriva Therapeutics AG (Director · Jul 24, 2018 – Jan 29, 2023 · Past); Otonomy Inc (Director · Aug 28, 2015 – Jun 21, 2022 · Past); Hyperion Therapeutics Inc (Director · Aug 11, 2014 – May 7, 2015 · Past); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Cadence Pharmaceuticals Inc (President, CEO, Director · Oct 24, 2006 – Mar 19, 2014 · Past) | Director · Jan 22, 2016 – May 20, 2020 · Past |
| Gino Santini Other companies: COMPASS Pathways Plc (CHAIRMAN OF THE BOARD · Since at least Sep 3, 2024); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 3, 2021 · Past); Vitae Pharmaceuticals Inc (Director · May 26, 2016 – Oct 25, 2016 · Past); AMAG Pharmaceuticals Inc (Director · May 19, 2016 – Nov 16, 2020 · Past); Horizon Pharma PLC (Director · May 3, 2016 – May 3, 2018 · Past); Intercept Pharmaceuticals Inc (Director · Nov 24, 2015 – Nov 8, 2023 · Past) | Chairman of the Board · Since at least Sep 10, 2015 |
| Carlos Paya Other companies: Vaxcyte, Inc. (President, Immune Design Corp Chairman, Vaxcyte · Since at least Oct 27, 2021); Mallinckrodt Inc (Director · May 22, 2019 – Jun 16, 2022 · Past); Standard BioTools Inc. (Director · Mar 23, 2017 – Jun 14, 2023 · Past); Immune Design Corp (President and CEO, Director · Oct 30, 2015 – Apr 2, 2019 · Past) | Director · Since at least May 15, 2025 |
| David Hirsch Other companies: Rapid Micro Biosystems, Inc. (Director · Jul 14, 2021 – May 23, 2024 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jul 23, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Molecular Templates Inc (Director · Aug 1, 2017 – Jun 3, 2022 · Past) | Director · May 6, 2015 – May 20, 2020 · Past |
| Garen Bohlin Other companies: Karyopharm Therapeutics Inc. (Director · Since at least Jun 16, 2016); Protara Therapeutics, Inc. (Director · Jun 9, 2016 – Jun 8, 2018 · Past); Tetraphase Pharmaceuticals Inc (Director · Jun 8, 2016 – Jun 10, 2019 · Past) | Director · Since at least Jun 9, 2016 |
| John A Fallon Other companies: EXACT Sciences Corporation (Director · Jan 25, 2016 – Jul 30, 2018 · Past); AMAG Pharmaceuticals Inc (Director · Sep 5, 2014 – Nov 16, 2020 · Past); Insulet Corporation (Director · Oct 24, 2012 – May 21, 2021 · Past) | Director · Since at least Jun 9, 2016 |
| Nancy S. Lurker Other companies: Alkermes plc (Director · Since at least Mar 5, 2024); EyePoint, Inc. (Director · Since at least Mar 29, 2019); Aquestive Therapeutics, Inc. (Director · Jun 13, 2019 – Jun 15, 2021 · Past) | Director · Since at least Feb 4, 2025 |
| Douglas R Carlson Other companies: Avalyn Pharma Inc. (See Remarks · Since at least Apr 29, 2026); ImageneBio, Inc. (COO & EVP of Finance · Mar 25, 2021 – Mar 25, 2021 · Past) | VP Corp. Devlp · May 6, 2015 – May 6, 2015 · Past |
| Paul Brannelly Other companies: Karyopharm Therapeutics Inc. (SVP, FINANCE & ADMIN, TREAS · Nov 5, 2013 – May 15, 2014 · Past) | Executive Vice President & CFO · May 6, 2015 – Feb 10, 2021 · Past |
All 31 people
| Person | Seat |
|---|---|
| Richard Malamut Other companies: Pelthos Therapeutics Inc. (Director · Since at least Feb 15, 2024) | EVP and Chief Medical Officer · Apr 1, 2019 – Feb 10, 2022 · Past |
| Vikram Karnani Other companies: Dyne Therapeutics, Inc. (Board Member · Since at least Dec 22, 2025) | PRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Nov 7, 2024 |
| Alison B Fleming | EVP & Chief Technical Officer · Jan 4, 2017 – Aug 10, 2021 · Past |
| Arun Padmanabhan | General Manager, Pain · Since at least Nov 5, 2026 |
| Barry S Duke | See remarks · May 6, 2015 – Mar 17, 2017 · Past |
| Colleen Tupper | Executive Vice President, Chief Financial Officer · Since at least May 24, 2021 |
| Danielle Jesse | Director, Investor Relations · Oct 29, 2025 – Nov 5, 2026 · Past |
| David Dieter | EVP & General Counsel · Since at least Mar 17, 2025 |
| Dean J. Patras | Chief People Officer · Since at least May 8, 2025 |
| Donovan Michael Glancy | Director · Since at least May 14, 2026 |
| Ian Karp | Vice President, Investor Relations · Oct 29, 2025 – Nov 5, 2026 · Past |
| Ingrid McPhilliamy | General Manager, ADHD · Since at least Oct 6, 2026 |
| Jane Gonnerman | Executive Vice President, Strategy & Corporate Development · Since at least May 8, 2025 |
| Jessica Cotrone | Senior Vice President, Corporate Communications & Corporate Affairs · Since at least Nov 5, 2026 |
| Jessica Cotrone Senior | Vice President, Corporate Communications & Corporate Affairs · Since at least Oct 21, 2026 |
| Michael G. Donovan | Director · Since at least Aug 6, 2026 |
| Rita Balice-Gordon | Director · Since at least Sep 24, 2020 |
| Scott Dreyer | EVP & Chief Commercial Officer · Since at least Jul 10, 2019 |
| Scott Sudduth | Executive Vice President, Head of Technical Operations · Since at least Nov 5, 2026 |
| Shirley R Kuhlmann | EVP and General Counsel · Nov 27, 2023 – Mar 4, 2025 · Past |
| Thomas Smith | EVP and Chief Medical Officer · Since at least Feb 12, 2024 |
Log in to ask 6ix AI your own questions about Collegium Pharmaceutical, Inc.